42 results about "Pollen allergen" patented technology

The present invention provides nucleic acid sequences coding for the Cryptomeria japonica major pollen allergen Cry j I, Cry j II, Jun s I and Jun v I and fragments or peptides thereof. The present invention also provides purified Cry j I, Cry j II, Jun s I and Jun v I and at least one fragment thereof produced in a host cell transformed with a nucleic acid sequence coding for Cry j I, Cry j II, Jun s I and Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I prepared synthetically. Cry j I, Cry j II, Jun s I and Jun v I and fragments thereof are useful for diagnosing, treating, and preventing Japanese cedar pollinosis. The present invention also provides isolated peptides of Cry j I and Cry j II. Peptides within the scope of the invention comprise at least one T cell epitope, or preferably at least two T cell epitopes of Cry j I or Cry j II. The invention also pertains to modified peptides having similar or enhanced therapeutic properties as the corresponding naturally-occurring allergen or portion thereof but having reduced side effects. Methods of treatment or of diagnosis of sensitivity to Japanese cedar pollens in an individual and therapeutic compositions, and multipeptide formulations comprising one or more peptides of the invention are also provided.

The T-cell epitope site on a Japanese cypress (hinoki) pollen allergen molecule has been identified by stimulating a T-cell line established from a patient suffering from Japanese cypress pollen allergy with an overlap peptide covering the primary structure of the Japanese cypress pollen allergen. The peptide is useful in peptide-based immunotherapy for patients with spring tree pollinosis including patients with Japanese cypress pollinosis having cross reactivity with Japanese cypress pollen. The peptide is also useful for diagnosing spring tree pollinosis.

The invention provides Artemisia pollen allergen vaccine lozenge and a preparation method thereof, wherein the lozenge is prepared by mixing idiotoxins of five kinds of sensitized Artemisia pollens and pharmaceutically acceptable carriers; and the five kinds of sensitized Artemisia plants are Artemisia sieversiana Willd, Artemisia annua L., Artemisia argyi Levl.et Vant, A.ordosica krasch and A.sphaerocep hala krasch. The Artemisia pollen allergen vaccine disclosed by the invention includes idiotoxins of five kinds of main sensitized Artemisia pollens in China; compared with the single Artemisia pollen allergen vaccine, the Artemisia pollen allergen vaccine disclosed by the invention is more effective; furthermore, compared with the sublingual drop, the sublingual lozenge is more steady; and the administration dosage is more accurate.

The invention discloses application of an acid buffer solution with the pH value of between 3.0 and 6.0 (the preferred pH value is between 4.0 and 5.0) in stabilizing the activity of pollen allergen. The invention also discloses a pharmaceutical composition, which contains at least one allergen from pollen, the acid buffer solution with the pH value of buffer effective amount of between 3.0 and 6.0, and a pharmaceutically acceptable carrier. The pharmaceutical composition can be stored, used and transported at normal temperature.

The present invention is drawn to antibody-mediated modulation of allergy. In this regard, the present invention discloses a monoclonal antibody, antigen-binding fragment or mimic thereof directed against Group 1 pollen allergens or homologues thereof. Also disclosed herein is the mechanism by which the disclosed monoclonal antibody, antigen binding fragment or mimic thereof will improve immunotherapy of allergic reactions in an individual. It is contemplated that herein that such a monoclonal antibody, antigen binding fragment or mimic thereof may also be useful in treatment of several microbial infections.